Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

"Salvage Use" of Recombinant Factor VIIa After Inadequate Haemostasis in Complex Cardiac Surgery

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified September 2005 by Austin Health.
Recruitment status was:  Recruiting
Information provided by:
Austin Health Identifier:
First received: September 14, 2005
Last updated: NA
Last verified: September 2005
History: No changes posted

Aims and Hypotheses:

This randomised placebo controlled study will test the hypothesis that Recombinant Activated Factor VII (rVIIa) will improve haemostasis after an inadequate response to conventional therapy in complex cardiac surgery.

Major bleeding is still of concern in complex cardiac surgery. It has been shown to be associated with poorer patient outcome and results in the consumption of resources (hospital costs, manpower and blood bank reserves). This study has the potential to provide evidence that rVIIa can reduce transfusion requirements and improve patient outcome in a problematic aspect of complicated cardiac surgery.

The objective is to conduct a multi-centre randomised placebo controlled study that has been designed to scientifically evaluate the treatment of post bypass coagulopathy in the association with complex cardiac surgery. The trial design is based on clinical practice that has evolved over 2 years at the Austin Hospital during which 38 patients have received open label administration of rVIIa. There is currently no published RCT in this area and there is no TGA approval for the use of rVIIa for this indication.

Condition Intervention Phase
Myocardial Ischemia
Blood Coagulation Disorders
Coronary Artery Disease
Heart Valve Diseases
Drug: Recombinant Activated Factor VII
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: "Salvage Use" of Recombinant Activated Factor VII After Inadequate Haemostatic Response to Conventional Therapy in Complex Cardiac Surgery - a Randomised Placebo Controlled Trial

Resource links provided by NLM:

Further study details as provided by Austin Health:

Primary Outcome Measures:
  • Adequate haemostasis to enable chest closure after administration of trial medication without the need for further intervention to improve coagulation.

Secondary Outcome Measures:
  • Percentage of cases that haemostasis after first administration of coagulation factors alone
  • Assessment of surgical field after administration of trial medication
  • Time to closure of chest after administration of trial medication
  • Transfusion requirements in post bypass period in theatre
  • Transfusion requirements in ICU first 12 hours
  • Mediastinal drainage in ICU first 12 hours
  • Coagulation study results at various sample times
  • Requirement for chest re-exploration
  • Ventilation duration in ICU
  • Duration of stay in ICU

Estimated Enrollment: 40
Study Start Date: June 2005
Estimated Study Completion Date: June 2008
  Show Detailed Description


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients with scheduled cardiac surgery undergoing the following procedures
  • Double valve replacements or repair.
  • Major thoracic aortic surgery including hypothermic circulatory arrest or descending aortic reconstruction.
  • Valve repair or replacement in the setting of endocarditis
  • Complex procedures requiring cardiopulmonary bypass duration anticipated to exceed 180 minutes in patients aged ³70 years

Exclusion Criteria:

  • Patient unable to give informed consent
  • Patient refusal
  • Allergy to rVIIa
  • Allergy to aprotinin or prior exposure within 6 months
  • Pre-existing congenital coagulopathy
  • Pre-existing hypercoagulable state
  • Patients in inclusion criteria whose actual bypass time does not exceed 180 minutes
  • Unresolved surgical bleeding
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00214656

Contact: Peter McCall, FANZCA 61 3 94965000 ext 3800
Contact: stephanie j Poustie, MPH 61 3 94965000 ext 3800

Australia, Victoria
Austin Health Recruiting
Melbourne, Victoria, Australia, 3084
Contact: Peter McCall, FANZCA    61 3 94965000 ext 3800   
Contact: Stephanie J Poustie, MPH    61 3 94965000 ext 3800   
Principal Investigator: Peter McCall, FANZCA         
Sponsors and Collaborators
Austin Health
Principal Investigator: Peter McCall, FANZCA Staff Anaesthetist
  More Information

Publications: Identifier: NCT00214656     History of Changes
Other Study ID Numbers: H2005/02047
Study First Received: September 14, 2005
Last Updated: September 14, 2005

Keywords provided by Austin Health:
Cardiac surgical procedures
Surgical blood loss
Surgical haemostasis
Factor VIIa

Additional relevant MeSH terms:
Coronary Artery Disease
Myocardial Ischemia
Coronary Disease
Heart Valve Diseases
Blood Coagulation Disorders
Hemostatic Disorders
Heart Diseases
Cardiovascular Diseases
Arterial Occlusive Diseases
Vascular Diseases
Pathologic Processes
Hematologic Diseases
Hemorrhagic Disorders processed this record on April 28, 2017